Kiniksa Pharmaceuticals

Tomorrow, September 4th, members of our management team will be participating in a fireside chat at the 2024 Wells Fargo Healthcare Conference. We welcome you to join us at 8:00 a.m. ET.    You can tune-in at the webcast link here: https://lnkd.in/eSWCm56N     A replay of the event will also be available on the Investors & Media section of Kiniksa’s website at: investors.kiniksa.com     #Kiniksa #HealthcareConference #InvestorRelations

Kiniksa is excited to announce that Prof. Massimo Imazio and Dr. Paul Cremer will be delivering two moderated presentations at ESC 2024! Join these two co-authors tomorrow, August 31st, as they present on the latest findings in recurrent pericarditis management. Don’t miss these insightful sessions at Station 5, Research Gateway.     Register for the event here: http://bit.ly/4e2ITqT     #ESCCongress #ESC2024 #RecurrentPericarditis #Pharmaceuticals

In honor of World Sjögren's Day, our team celebrated yesterday by wearing blue and gathering together to show our support.   At Kiniksa Pharmaceuticals, we are proud to contribute to the fight against this challenging condition. Recently, we commenced enrollment in our Phase 2b clinical trial for our investigational drug, marking a significant milestone in our commitment to advancing treatment options.   We invite you to join us in raising awareness for Sjögren's Disease, a serious and systemic autoimmune disease that affects millions.  Together, we can make a difference.    Check out the Sjögren’s Foundation Fact Sheet and Infographic for more information on this important cause, as well as visit their website to learn more: www.sjogrens.org      Let’s spread the word and help make Sjögren's a more recognized and understood disease. #WorldSjögrensDay #SjögrensAwareness #WearBlue #AutoimmuneDisease #EverySecondCounts #TeamKiniksa 

Today, we announced our Q2 2024 financial results, and we’re excited to share that we are making progress across our entire portfolio. Join our live investor webcast at 8:30 a.m. ET or read our press release here: https://lnkd.in/eSFfDCT5

🔬We are thrilled to announce that Kiniksa Pharmaceuticals has commenced enrollment of the Phase 2b clinical trial of abiprubart in Sjögren’s Disease. With abiprubart, an investigational humanized anti-CD40 monoclonal antibody designed to inhibit the CD40-CD154 (CD40 ligand) interaction, Kiniksa aims to address this chronic autoimmune disorder that currently has no FDA-approved therapies. This marks a significant milestone in our mission to provide innovative treatments for patients with significant unmet medical needs. Learn more about today’s announcement in the press release here: https://lnkd.in/eVU4_AHb #Biopharma #ClinicalTrials #SjögrensDisease #EverySecondCounts #Kiniksa

Kiniksa is proud to partner with Hall-of-Famer, Henrik Lundqvist, to raise awareness of recurrent pericarditis. To learn more, check out today’s announcement here: https://lnkd.in/eqBaFdEp   #EverySecondCounts #RecurrentPericarditis #Kiniksa #HenrikLundqvist

Kiniksa is proud to be sponsoring the American Heart Association ‘Addressing Recurrent Pericarditis’ initiative https://bit.ly/3VveQjV

April is Sjögren’s Awareness Month. Kiniksa is proud to support the Sjögren’s Foundation through our corporate membership and to have hosted Dr. Lane Destro at our recent company town hall meeting, as we recognize the many people affected by this disease.

https://bit.ly/44biSSk

For patients with recurrent pericarditis (RP), their struggle can last for years. They suffer not only during flares, but in between flares as well. Join us at Booth 3719 at #ACC24 or visit our virtual booth at https://bit.ly/3VwJStj to learn more about the impact of RP and how it may be treated.